publication . Article . Other literature type . 2020

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Franck Touret; Magali Gilles; Karine Barral; Antoine Nougairède; Jacques van Helden; Etienne Decroly; Xavier de Lamballerie; Bruno Coutard;
Open Access
  • Published: 04 Aug 2020 Journal: Scientific Reports, volume 10 (eissn: 2045-2322, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
  • Country: France
Abstract
Abstract A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 com...
Persistent Identifiers
Subjects
free text keywords: Multidisciplinary, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Article, Drug discovery, SARS-CoV-2, In vivo, Repurposing, Antibiotics, medicine.drug_class, medicine, Drug repositioning, In vitro, Coronavirus, medicine.disease_cause, Chemical library, chemistry.chemical_compound, chemistry, Drug development, Pharmacology, business.industry, business, lcsh:Medicine, lcsh:R, lcsh:Science, lcsh:Q
Funded by
EC| EVA-GLOBAL
Project
EVA-GLOBAL
European Virus Archive GLOBAL
  • Funder: European Commission (EC)
  • Project Code: 871029
  • Funding stream: H2020 | RIA
Validated by funder
Communities
COVID-19
33 references, page 1 of 3

1. de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523-534 (2016). [OpenAIRE]

2. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199-1207 (2020).

3. Callaway, E., Cyranoski, D., Mallapaty, S., Stoye, E. & Tollefson, J. eTh coronavirus pandemic in vfie powerful charts. Nature (2020).

4. Li, G. & De Clercq, E. eThrapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149-150 (2020). [OpenAIRE]

5. Cheng, Y.-S., Williamson, P. R. & Zheng, W. Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr. Opin. Pharmacol. 48, 92-98 (2019).

6. Manganaro, R. et al. Synthesis and antiviral eefct of novel ufloxetine analogues as enterovirus 2C inhibitors. Antiviral Res. 178, 104781 (2020).

7. de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875-4884 (2014).

8. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885-4893 (2014).

9. Mercorelli, B., Palù, G. & Loregian, A. Drug repurposing for viral infectious diseases: how far are we?. Trends Microbiol. 26, 865-876 (2018). [OpenAIRE]

10. Delang, L. et al. eTh viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6, 31819 (2016).

11. Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 168, 109-113 (2019). [OpenAIRE]

12. Blaising, J., Polyak, S. J. & Pécheur, E.-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 107, 84-94 (2014). [OpenAIRE]

13. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is eefctive in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).

14. Wang, M. et al. Remdesivir and chloroquine eefctively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 1, 1-3 (2020).

15. Yao, X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. (2020).

33 references, page 1 of 3
Any information missing or wrong?Report an Issue